Overview
Notes
Bayer Links
Investor Relations
11. Other operating expenses
2007 | 2008 | |
|---|---|---|
€ million | € million | |
Losses from sales of noncurrent assets and from divestitures | (52 ) | (23 ) |
Write-downs of receivables | (98 ) | (113 ) |
Expenses related to significant legal risks | (139 ) | (106 ) |
Recognition of exchange rate hedges | (57 ) | (193 ) |
Miscellaneous operating expenses | (1,223 ) | (983 ) |
Total | (1,569 ) | (1,418 ) |
The principal restructuring expenses included in miscellaneous operating expenses for 2008 amount to €404 million (2007: €709 million), including €157 million related to the integration of the Schering Group (2007: €506 million). Further details of restructuring expenses are given in Note [26.3] .
Miscellaneous operating expenses for 2008 included €62 million in write-downs of intangible assets. In the previous year, other operating expenses principally comprised a write-down of €152 million necessitated by the findings of the BEYOND study on
Betaferon®/Betaseron®.
An amount of €517 million (2007: €362 million) relates to a large number of individually immaterial items within the subsidiaries.
back to overview
Miscellaneous operating expenses for 2008 included €62 million in write-downs of intangible assets. In the previous year, other operating expenses principally comprised a write-down of €152 million necessitated by the findings of the BEYOND study on
Betaferon®/Betaseron®. An amount of €517 million (2007: €362 million) relates to a large number of individually immaterial items within the subsidiaries.
back to overview
Bookmark this page
E-mail this page
Advanced Search
